We cover new discoveries to improve healthcare out of Switzerland that could have a global impact.
More
Drugmakers reassess Europe as Trump overhauls drug-pricing rules
This content was published on
President Trump’s drug-pricing overhaul has triggered an earthquake in Europe as drugmakers scramble to protect their bottom lines.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Can Saudi Arabia’s billions unlock the secrets to a longer, healthier life?
This content was published on
Longevity has been an underfunded area of biotech research but that is changing thanks to an unlikely source: Saudi Arabia.
This content was published on
Nearly 30 years ago an academic paper wrongly linked autism to a measles vaccine. The impacts are still being felt today.
Global concern over measles is rising. Should Switzerland worry?
This content was published on
Measles is making a global comeback. In Switzerland, a crisis is unlikely – but authorities warn a strong vaccination rate remains crucial.
Novartis bets on ageing as next frontier in drug development
This content was published on
Swiss pharma giant Novartis is diving into research on ageing to tap the growing market for drugs that help keep older adults healthy.
This content was published on
People have come to Switzerland for centuries in search of the fountain of youth. How did the country become a magnet for longevity seekers?
Longevity clinics: modern-day snake oil or the key to healthy ageing?
This content was published on
Scientists have yet to find the elixir of life but this hasn’t stopped longevity clinics from selling treatments, pills and gadgets that claim to slow ageing.
‘It’s political’: why some people refuse to have a smartphone
This content was published on
Almost two decades after the first iPhone, not everyone is ready to go fully digital. We talk to three people sceptical of the always-online life.
Digital democracy: will Swiss signature scandal pave way for e-collecting?
This content was published on
It remains to be seen whether the signature scam will bring about the digitalisation of direct democracy in Switzerland. An overview of the situation.
From London to Lausanne: how Isomorphic Labs is rewriting drug discovery
This content was published on
Google DeepMind spin-off Isomorphic Labs is expanding in Switzerland to achieve its ambitious goal to “solve all diseases” with AI.
Electric touch: neurostimulation’s comeback in psychiatry
This content was published on
Faced with a lack of breakthroughs in treating mental health disorders, older methods such as electrical-based therapies are experiencing a revival.
Digital citizens could shake up democracy in Switzerland and beyond
This content was published on
Leading experts in medicine and business are pinning their hopes on digital twins. Two economists have a bold proposal that could reshape democracy.
This content was published on
In episode 6 of this season’s Swiss Connection science podcast, we look at the role of relationships and perceptions in longevity.
Science podcast: the story behind the ‘longevity pill’ rapamycin
This content was published on
In episode 5 of this season’s Swiss Connection science podcast, we talk about the discovery of TOR and its potential for longevity.
Science podcast: Can gender diversity create better medicine?
This content was published on
In episode 3 of this season’s Swiss Connection science podcast we look at the role of sex and gender in drug development.
Under-50s cancer patients face system unprepared for them
This content was published on
Countries, including Switzerland, are struggling to deal with the challenges posed by rising cancer rates among people under 50.
Switzerland no longer wants to foot the bill for ‘suicide tourism’
This content was published on
In Switzerland, all deaths through assisted suicide must be followed by a medical and legal investigation. This entails considerable costs for the state.
This content was published on
In episode 6 of this season’s Swiss Connection science podcast, we look at the role of relationships and perceptions in longevity.
Science podcast: the story behind the ‘longevity pill’ rapamycin
This content was published on
In episode 5 of this season’s Swiss Connection science podcast, we talk about the discovery of TOR and its potential for longevity.
This content was published on
Medical experts now use artificial intelligence to help them diagnose and monitor diseases. But does this mean AI will replace doctors?
From London to Lausanne: how Isomorphic Labs is rewriting drug discovery
This content was published on
Google DeepMind spin-off Isomorphic Labs is expanding in Switzerland to achieve its ambitious goal to “solve all diseases” with AI.
Science podcast: Can gender diversity create better medicine?
This content was published on
In episode 3 of this season’s Swiss Connection science podcast we look at the role of sex and gender in drug development.
What lies ahead for Switzerland: an economic outlook for 2026
This content was published on
in 2026, the Swiss economy will face downward pressure from weaker domestic demand and ongoing uncertainty related to US import tariffs.
US trade deal forces reckoning for Swiss pharma powerhouse
This content was published on
Swiss pharma made massive investment promises to the US that are fueling anxiety about the industry’s future in Switzerland.
Under-50s cancer patients face system unprepared for them
This content was published on
Countries, including Switzerland, are struggling to deal with the challenges posed by rising cancer rates among people under 50.
This content was published on
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of obesity medicine.
Why a prospering Irish Nestlé factory is closing down
This content was published on
China’s baby boom enriched a small Irish town where a Nestlé factory made formula for Chinese newborns. Then a baby bust unraveled it all. Or so it seemed.
How private equity oversees the ethics of drug research
This content was published on
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
How a clash with Roche exposed cracks in Swiss drug pricing system
This content was published on
Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.
When diagnosing a disease does more harm than good
This content was published on
Switzerland has the highest number of MRI scanners per person in Europe. But more screening doesn’t always lead to better health outcomes.
Can Saudi Arabia’s billions unlock the secrets to a longer, healthier life?
This content was published on
Longevity has been an underfunded area of biotech research but that is changing thanks to an unlikely source: Saudi Arabia.
